Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kellogg settles with FTC

This article was originally published in The Tan Sheet

Executive Summary

Kellogg Co. settles Federal Trade Commission allegations that it falsely advertised Frosted Mini-Wheats as "clinically shown to improve kids' attentiveness by nearly 20 percent." The commission alleged that the study Kellogg relied on for the claim shows only one in nine children's attentiveness improved by 20 percent or more, according to an April 20 FTC release. The commission also alleged that the study shows children who ate the cereal for breakfast were on average 11 percent more attentive than those who skipped breakfast. This contradicts the company's claim that attentiveness improved 20 percent, the commission says. The settlement prohibits Kellogg from making unsubstantiated claims and misrepresenting study results, but does not impose a fine or consumer redress

You may also be interested in...

FTC finalizes Kellogg consent order

The Federal Trade Commission approves a final consent order to resolve allegations Kellogg Company falsely advertised Frosted Mini-Wheats as "clinically shown to improve kids' attentiveness nearly 20 percent." The Commission said data Kellogg relied on to make the claim was self-contradictory and did not support the statement (1"The Tan Sheet" April 27, 2009)

Zydus Cadila Testing Three-Dose COVID-19 Vaccine

Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.

Six Questions For Sun Pharma MD Shanghvi

Sun Pharma’s founder and MD shares with Scrip his views on some key big picture issues, including leveraging pandemic-related regulatory experience for urgently needed products, expectations in the US market, the outlook for M&A, and the potential of e-pharmacies in India.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts